Storia in 6 fonti

Celcuity gains FDA approval for closely watched breast cancer drug

Still, shares fell by nearly 20% after the company revealed a delay in the coming launch of Revtorpyk. Details in the drug’s prescribing information surprised some analysts, too.

Raccontata da

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

biopharmadive.comStai leggendo1 mese fa

Celcuity gains FDA approval for closely watched breast cancer drug

Still, shares fell by nearly 20% after the company revealed a delay in the coming launch of Revtorpyk. Details in the drug’s prescribing information surprised some analysts, too.

originale

Timeline cronologica

martedì 14 luglio 2026·endpoints.news
Celcuity wins approval for breast cancer drug Revtorpyk
Celcuity's Revtorpyk wins FDA approval for use in HR+/HER2- breast cancer without a PIK3CA mutation.
martedì 14 luglio 2026·fiercepharma.com
With FDA approval for its breast cancer blockbuster hopeful, Celcuity could ‘belong in the hands’ of a Big Pharma
The FDA has approved a new | The FDA has approved a new small molecule inhibitor from Celcuity with blockbuster potential that could become a new standard-of-care for patients…

Celcuity gains FDA approval for closely watched breast cancer drug

Confronto fonti

Celcuity gains FDA approval for closely watched breast cancer drug

Timeline cronologica

Celcuity wins approval for breast cancer drug Revtorpyk

With FDA approval for its breast cancer blockbuster hopeful, Celcuity could ‘belong in the hands’ of a Big Pharma

Celcuity got its cancer drug approved. Then its stock dipped

Correction to Celcuity Gets FDA Approval Headline

FDA approves Revtorpyk for hormone receptor-positive, HER2-negative breast cancer

With FDA approval for its breast cancer blockbuster hopeful, Celcuity could ‘belong in the hands’ of a Big…

FDA approves breast cancer drug that cut progression risk by 76%

Correction to Celcuity Gets FDA Approval Headline

Celcuity gains FDA approval for closely watched breast cancer drug

FDA approves Revtorpyk for hormone receptor-positive, HER2-negative breast cancer

FDA approves breast cancer drug that cut progression risk by 76%

Celcuity got its cancer drug approved. Then its stock dipped